22 June 2021 - 12:00-16:30

CBW8 EAN/INUS: How to manage neurogenic urogenital and bowel dysfunction by the practicing neurologist

1: Assessment and treatment of bladder dysfunction
Helmut Madersbacher, Rum, Austria

2: Approach to the management of sexual dysfunction
Jalesh Panicker, London, United Kingdom

3: Tips and tricks to the management of bowel dysfunction
Katarina Tudor, Zagreb, Croatia

1: TLOC: listen carefully, look closely
Alessandra Fanciulli, Innsbruck, Austria

2: Syncope, seizure or something else?
Roland Thijs, Heemstede, The Netherlands

3: The dangerous syncope I shouldn’t overlook
Michele Brignole, Lavagna, Italy

SPS13 Gender and Diversity Taskforce: How sex and gender differences may impact research and clinical practice in neurology

1: The impact of sex and gender on the history of global health and care in neurology
Sanjoy Bhattacharya, York, England

2: Sex-related differences in genetic neurological disorders
Christine Klein, Lübeck, Germany

3: Impact of sex and gender on research and clinical management of migraine
Elena Lebedeva, Yekaterinburg, Russian Federation

4: The new perspective in sex and gender-oriented management of neurological disorders  
Gennarina Arabia, Catanzaro, Italy

TBA

1: Brain-heart axis and central lesions inducing autonomic dysfunction
Max Hilz, Erlangen, Germany

2: Central ANS dysfunction and brain-heart interactions: from physiological profiling to functional imaging
Jens Jordan, Cologne, Germany

3: Intracranial Pressure and sympathetic activity
Anne Pavy-Le Traon, Toulouse, France

4: Neurocardiac axis: Heart’effects on brain in heart failure
 Constandina Arvanitis, Toulouse, France

1: Introduction; Injectables: Interferon-beta, Glatiramer Acetate
Ron Milo, Ashkelon, Israel

2: Oral therapies: S1P modulators, DMF, Teriflunomide
Celia Oreja-Guevara, Madrid, Spain

3: Monoclonal antibodies: natalizumab, Anti-CD20 mAbs and other B cell-targeted therapies
Paul Friedemann, Berlin, Germany

4: Immune reconstitution therapies: Alemtuzumab, Cladribine, HSCT
Tjalf Ziemssen, Dresden, Germany

1: Stroke Prevention in AF
Maurizio Paciaroni, Perugia, Italy

2: Antiplatelet and Lipid Management
Gian Marco De Marchis, Basel, Switzerland

3: Antithrombotic Therapy in Cerebral vein thrombosis
Diana Aguiar de Sousa, Lisbon, Portugal

4: Secondary Prevention after Intracerebral Haemorrhage
Charlotte Cordonnier, Lille, France

1: What information from imaging does the neurologist need to optimize management, in view of the new WHO classification?
Giulia Berzero, Paris, France

2: How can neuroimaging contribute to the diagnosis of brain tumours: Role of conventional, spectroscopy and perfusion MRI
Ana Ramos, Madrid, Spain

3: Pre- and intraoperative imaging essential to neurosurgery: fMRI, DTI, intraoperative imaging
Tarek Yousry, London, United Kingdom

4: Differentiating tumour recurrence from treatment effect: What should be used and how does it help?
Nicoletta Anzalone, Milan, Italy

1: Precision diagnosis of repeats using long-read sequencing and overview of the common and recently identified repeat expansion disorders
Henry Houlden, London, United Kingdom

2: Clinical features with video examples, management and important red flags in exonic CAG repeat expansion disorders such as SCAs, MD, DRPLA
Sylvia Boesch, Innsbruck, Austria

3: Clinical features with video examples, management and important red flags of intronic repeat disorders such as FRDA, CANVAS
Josef Finsterer, Vienna, Austria

4: Disease mechanisms, therapeutic targets and current trials in repeat expansion disorders
TBA

CON4 EAN/MDS-ES Challenges in translational neurosciences & Treatment of severe forms of multiple sclerosis

1: Are Stem Cells Ready for Clinical Use in Movement Disorders – Yes
TBA

2: Are Stem Cells Ready for Clinical Use in Movement Disorders – No
Joaquim Ferreira, Lisbon, Portugal

3: Autologous hematopoietic stem cell transplantation is the most effective therapy for severe forms of multiple sclerosis
Joachim Burman, Uppsala, Sweden

4: In severe forms of multiple sclerosis we have approved treatments that are very effective with a acceptable safety profile
Ludwig Kappos, Basel, Switzerland